Review of the year 2013: Retina 2013

Article

2013 has been an important year in retina therapy, with increased information released on nutritional supplements for AMD patients, widened indications for anti-VEGFs and the approval of treatment for symptomatic vitreomacular adhesion.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Related Content
A person speaks on a stage during a conference/lecture. Concept image for 2025 EURETINA European Society of Retina specialists scientific meeting. Image credit: ©Anton Gvozdikov – stock.adobe.com

The Eye Care Network's clinical advisors will present at EURETINA

Hattie Hayes
August 27th 2025
Article
PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

August 27th 2025
Podcast
A pharmacy in Montreal, Quebec, its "pharmacie" sign in French. Concept image for RAMQ approval of Vabysmo faricimab injection roche for macular oedema secondary to retinal vein occlusion. Image credit: ©Andriy Blokhin – stock.adobe.com

Québec announces faricimab (Vabysmo, Roche) will be funded for macular oedema secondary to RVO

Martin David Harp
August 27th 2025
Article
PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

August 27th 2025
Podcast
Tyson J. Brunstetter, MBA, OD, PhD, FAAO, FAsMA presents a keynote on spaceflight-associated neuro-ocular syndrome (SANS). (All images courtesy of Heidelberg Engineering)

Recap: The future of imaging is out of this world

Hattie Hayes
August 27th 2025
Article
A glass building with a sign reading "RESERVE BANK." There are $100 Australian bank notes superimposed over the image. Concept image for Mirugen funding, cell reprogramming biologic biotech business of retina care news. Image credit: ©Rose Makin – stock.adobe.com

Australian biotech firm Mirugen secures major funding for cell reprogramming therapy

Hattie Hayes
August 27th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.